nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Nephritis—Methimazole—Graves' disease	0.105	0.198	CcSEcCtD
Dabrafenib—Nephritis—Propylthiouracil—Graves' disease	0.0897	0.168	CcSEcCtD
Dabrafenib—NEK11—thyroid gland—Graves' disease	0.0466	0.11	CbGeAlD
Dabrafenib—LIMK1—adipose tissue—Graves' disease	0.0385	0.0906	CbGeAlD
Dabrafenib—LIMK1—thyroid gland—Graves' disease	0.0334	0.0784	CbGeAlD
Dabrafenib—SIK1—connective tissue—Graves' disease	0.026	0.061	CbGeAlD
Dabrafenib—Renal failure acute—Propylthiouracil—Graves' disease	0.0241	0.0451	CcSEcCtD
Dabrafenib—BRAF—pituitary gland—Graves' disease	0.0239	0.0562	CbGeAlD
Dabrafenib—BRAF—adipose tissue—Graves' disease	0.0238	0.0559	CbGeAlD
Dabrafenib—RAF1—eye—Graves' disease	0.0215	0.0504	CbGeAlD
Dabrafenib—RAF1—connective tissue—Graves' disease	0.0207	0.0486	CbGeAlD
Dabrafenib—BRAF—thyroid gland—Graves' disease	0.0206	0.0484	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—Graves' disease	0.0206	0.0484	CbGeAlD
Dabrafenib—SIK1—pituitary gland—Graves' disease	0.02	0.047	CbGeAlD
Dabrafenib—SIK1—adipose tissue—Graves' disease	0.0199	0.0468	CbGeAlD
Dabrafenib—SIK1—thyroid gland—Graves' disease	0.0173	0.0405	CbGeAlD
Dabrafenib—Alopecia—Methimazole—Graves' disease	0.016	0.0299	CcSEcCtD
Dabrafenib—RAF1—pituitary gland—Graves' disease	0.0159	0.0374	CbGeAlD
Dabrafenib—RAF1—adipose tissue—Graves' disease	0.0159	0.0373	CbGeAlD
Dabrafenib—Haemoglobin—Propylthiouracil—Graves' disease	0.0155	0.029	CcSEcCtD
Dabrafenib—Haemorrhage—Propylthiouracil—Graves' disease	0.0154	0.0288	CcSEcCtD
Dabrafenib—Leukopenia—Methimazole—Graves' disease	0.0141	0.0264	CcSEcCtD
Dabrafenib—RAF1—thyroid gland—Graves' disease	0.0137	0.0323	CbGeAlD
Dabrafenib—Alopecia—Propylthiouracil—Graves' disease	0.0136	0.0255	CcSEcCtD
Dabrafenib—Myalgia—Methimazole—Graves' disease	0.0134	0.0251	CcSEcCtD
Dabrafenib—Arthralgia—Methimazole—Graves' disease	0.0134	0.0251	CcSEcCtD
Dabrafenib—Oedema—Methimazole—Graves' disease	0.0129	0.0241	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methimazole—Graves' disease	0.0126	0.0236	CcSEcCtD
Dabrafenib—SLC22A8—eye—Graves' disease	0.0125	0.0293	CbGeAlD
Dabrafenib—Leukopenia—Propylthiouracil—Graves' disease	0.012	0.0225	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methimazole—Graves' disease	0.0117	0.0219	CcSEcCtD
Dabrafenib—Arthralgia—Propylthiouracil—Graves' disease	0.0114	0.0214	CcSEcCtD
Dabrafenib—Myalgia—Propylthiouracil—Graves' disease	0.0114	0.0214	CcSEcCtD
Dabrafenib—Oedema—Propylthiouracil—Graves' disease	0.0109	0.0205	CcSEcCtD
Dabrafenib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.0107	0.02	CcSEcCtD
Dabrafenib—Body temperature increased—Methimazole—Graves' disease	0.0102	0.019	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00996	0.0187	CcSEcCtD
Dabrafenib—Pruritus—Methimazole—Graves' disease	0.00909	0.017	CcSEcCtD
Dabrafenib—Body temperature increased—Propylthiouracil—Graves' disease	0.00864	0.0162	CcSEcCtD
Dabrafenib—Vomiting—Methimazole—Graves' disease	0.00817	0.0153	CcSEcCtD
Dabrafenib—Rash—Methimazole—Graves' disease	0.0081	0.0152	CcSEcCtD
Dabrafenib—Dermatitis—Methimazole—Graves' disease	0.0081	0.0152	CcSEcCtD
Dabrafenib—Headache—Methimazole—Graves' disease	0.00805	0.0151	CcSEcCtD
Dabrafenib—Pruritus—Propylthiouracil—Graves' disease	0.00773	0.0145	CcSEcCtD
Dabrafenib—Nausea—Methimazole—Graves' disease	0.00763	0.0143	CcSEcCtD
Dabrafenib—Vomiting—Propylthiouracil—Graves' disease	0.00695	0.013	CcSEcCtD
Dabrafenib—Rash—Propylthiouracil—Graves' disease	0.00689	0.0129	CcSEcCtD
Dabrafenib—Dermatitis—Propylthiouracil—Graves' disease	0.00688	0.0129	CcSEcCtD
Dabrafenib—Headache—Propylthiouracil—Graves' disease	0.00685	0.0128	CcSEcCtD
Dabrafenib—CYP2C8—pituitary gland—Graves' disease	0.00678	0.0159	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—Graves' disease	0.00659	0.0155	CbGeAlD
Dabrafenib—ABCG2—adipose tissue—Graves' disease	0.00656	0.0154	CbGeAlD
Dabrafenib—Nausea—Propylthiouracil—Graves' disease	0.00649	0.0122	CcSEcCtD
Dabrafenib—ABCG2—thyroid gland—Graves' disease	0.00568	0.0133	CbGeAlD
Dabrafenib—ABCB1—pituitary gland—Graves' disease	0.00325	0.00763	CbGeAlD
Dabrafenib—ABCB1—adipose tissue—Graves' disease	0.00324	0.0076	CbGeAlD
Dabrafenib—ABCB1—thyroid gland—Graves' disease	0.0028	0.00658	CbGeAlD
Dabrafenib—LIMK1—Caspase Cascade in Apoptosis—FASLG—Graves' disease	0.0014	0.0345	CbGpPWpGaD
Dabrafenib—LIMK1—Caspase Cascade in Apoptosis—FAS—Graves' disease	0.00135	0.0332	CbGpPWpGaD
Dabrafenib—BRAF—TSH signaling pathway—TSHR—Graves' disease	0.00121	0.0298	CbGpPWpGaD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.000979	0.0241	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—HLA-DRB1—Graves' disease	0.000888	0.0219	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—FAS—Graves' disease	0.000876	0.0216	CbGpPWpGaD
Dabrafenib—RAF1—CXCR3-mediated signaling events—CXCL10—Graves' disease	0.00084	0.0207	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—TSHR—Graves' disease	0.000835	0.0206	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.000736	0.0181	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.000678	0.0167	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.000662	0.0163	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—CD4—Graves' disease	0.000627	0.0154	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.000622	0.0153	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—GABRA3—Graves' disease	0.000603	0.0149	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.000596	0.0147	CbGpPWpGaD
Dabrafenib—RAF1—IL-2 Signaling Pathway—IL2RA—Graves' disease	0.000592	0.0146	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.00059	0.0145	CbGpPWpGaD
Dabrafenib—LIMK1—Caspase Cascade in Apoptosis—TNF—Graves' disease	0.000573	0.0141	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—GABRA3—Graves' disease	0.000564	0.0139	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-2 signaling—IL2RA—Graves' disease	0.000541	0.0133	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.000509	0.0126	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—ICAM1—Graves' disease	0.000495	0.0122	CbGpPWpGaD
Dabrafenib—RAF1—IL2-mediated signaling events—IL2RA—Graves' disease	0.000484	0.0119	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.000458	0.0113	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IL2RA—Graves' disease	0.000458	0.0113	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.00043	0.0106	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.000413	0.0102	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000408	0.0101	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IFIH1—Graves' disease	0.000401	0.00988	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000393	0.0097	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—GABRA3—Graves' disease	0.00039	0.00962	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD8A—Graves' disease	0.000357	0.0088	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000333	0.0082	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—FAS—Graves' disease	0.000324	0.00798	CbGpPWpGaD
Dabrafenib—RAF1—IL2-mediated signaling events—IFNG—Graves' disease	0.00032	0.00788	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HLA-E—Graves' disease	0.000315	0.00777	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IFNG—Graves' disease	0.000302	0.00744	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HLA-E—Graves' disease	0.000298	0.00735	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—FASLG—Graves' disease	0.000295	0.00726	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000294	0.00725	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—FAS—Graves' disease	0.000284	0.007	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HLA-E—Graves' disease	0.000281	0.00692	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL2RA—Graves' disease	0.000278	0.00686	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000272	0.00671	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IFNG—Graves' disease	0.000271	0.00669	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00026	0.00642	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000255	0.00628	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—TNF—Graves' disease	0.000253	0.00623	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000252	0.00622	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000247	0.00608	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000243	0.00599	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL1B—Graves' disease	0.000242	0.00597	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000235	0.0058	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFIH1—Graves' disease	0.000233	0.00575	CbGpPWpGaD
Dabrafenib—RAF1—Ceramide signaling pathway—TNF—Graves' disease	0.000227	0.0056	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HLA-B—Graves' disease	0.000225	0.00554	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000224	0.00551	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—IL1B—Graves' disease	0.000219	0.0054	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000217	0.00535	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00021	0.00517	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD4—Graves' disease	0.000205	0.00506	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000204	0.00502	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FASLG—Graves' disease	0.000204	0.00502	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.0002	0.00493	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HLA-B—Graves' disease	0.0002	0.00493	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000198	0.00487	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FAS—Graves' disease	0.000197	0.00484	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.000194	0.00479	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL1B—Graves' disease	0.000189	0.00467	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IFNG—Graves' disease	0.000188	0.00463	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000184	0.00453	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-E—Graves' disease	0.000184	0.00453	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000183	0.00451	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.00018	0.00443	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40—Graves' disease	0.000179	0.00442	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000177	0.00437	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CTLA4—Graves' disease	0.000177	0.00436	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000176	0.00434	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000176	0.00433	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000169	0.00418	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000168	0.00415	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—Graves' disease	0.000167	0.00413	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000167	0.00411	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—IL1B—Graves' disease	0.000166	0.0041	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL1B—Graves' disease	0.000164	0.00404	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000157	0.00387	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000154	0.0038	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000152	0.00375	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GC—Graves' disease	0.000148	0.00365	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-DQB1—Graves' disease	0.000146	0.00359	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000145	0.00358	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IFIH1—Graves' disease	0.000139	0.00342	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000139	0.00341	CbGpPWpGaD
Dabrafenib—BRAF—Disease—B3GNT2—Graves' disease	0.000138	0.00341	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD8A—Graves' disease	0.000136	0.00335	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—Graves' disease	0.000135	0.00333	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—Graves' disease	0.000134	0.00331	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-B—Graves' disease	0.000131	0.00322	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.00013	0.0032	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000129	0.00317	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000128	0.00316	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2RA—Graves' disease	0.000123	0.00302	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-A—Graves' disease	0.000121	0.00299	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—Graves' disease	0.000121	0.00297	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000117	0.00289	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—IL1B—Graves' disease	0.000115	0.00283	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000113	0.00277	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—B3GNT2—Graves' disease	0.000112	0.00277	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000111	0.00274	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-DRB1—Graves' disease	0.000111	0.00273	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HLA-E—Graves' disease	0.000109	0.00269	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ICAM1—Graves' disease	0.000106	0.00262	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-E—Graves' disease	0.000105	0.00258	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40—Graves' disease	0.000102	0.00252	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—Graves' disease	0.000102	0.00251	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CTLA4—Graves' disease	0.000101	0.00249	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GC—Graves' disease	9.96e-05	0.00245	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL1B—Graves' disease	9.92e-05	0.00244	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	9.9e-05	0.00244	CbGpPWpGaD
Dabrafenib—RAF1—Disease—B3GNT2—Graves' disease	9.57e-05	0.00236	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TSHR—Graves' disease	9.4e-05	0.00232	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GC—Graves' disease	9.22e-05	0.00227	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	8.67e-05	0.00214	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Graves' disease	8.57e-05	0.00211	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	8.36e-05	0.00206	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—Graves' disease	8.34e-05	0.00206	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DQB1—Graves' disease	8.31e-05	0.00205	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—Graves' disease	8.09e-05	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2RA—Graves' disease	8.09e-05	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFIH1—Graves' disease	8.07e-05	0.00199	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSHR—Graves' disease	8.02e-05	0.00198	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—Graves' disease	7.81e-05	0.00193	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HLA-B—Graves' disease	7.77e-05	0.00191	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—Graves' disease	7.76e-05	0.00191	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Graves' disease	7.64e-05	0.00188	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—B3GNT2—Graves' disease	7.55e-05	0.00186	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	7.53e-05	0.00186	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-B—Graves' disease	7.46e-05	0.00184	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—Graves' disease	7.21e-05	0.00178	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—Graves' disease	7.19e-05	0.00177	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—B3GNT2—Graves' disease	6.99e-05	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-A—Graves' disease	6.91e-05	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-E—Graves' disease	6.35e-05	0.00157	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DRB1—Graves' disease	6.32e-05	0.00156	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40—Graves' disease	6.21e-05	0.00153	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTLA4—Graves' disease	6.12e-05	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL10—Graves' disease	6.07e-05	0.0015	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ICAM1—Graves' disease	6.06e-05	0.00149	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GC—Graves' disease	5.72e-05	0.00141	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HLA-A—Graves' disease	5.6e-05	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSHR—Graves' disease	5.55e-05	0.00137	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL10—Graves' disease	5.19e-05	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—Graves' disease	5.04e-05	0.00124	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GC—Graves' disease	4.99e-05	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—Graves' disease	4.7e-05	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2RA—Graves' disease	4.64e-05	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—Graves' disease	4.64e-05	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—Graves' disease	4.53e-05	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—Graves' disease	4.45e-05	0.0011	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—B3GNT2—Graves' disease	4.34e-05	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2RA—Graves' disease	4.24e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-A—Graves' disease	4.19e-05	0.00103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2RA—Graves' disease	3.96e-05	0.000977	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HLA-A—Graves' disease	3.87e-05	0.000954	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—Graves' disease	3.83e-05	0.000944	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—B3GNT2—Graves' disease	3.78e-05	0.000931	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—Graves' disease	3.68e-05	0.000906	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—Graves' disease	3.61e-05	0.000889	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL10—Graves' disease	3.59e-05	0.000884	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.55e-05	0.000875	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—Graves' disease	3.52e-05	0.000868	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GC—Graves' disease	3.07e-05	0.000757	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—Graves' disease	2.8e-05	0.00069	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2RA—Graves' disease	2.74e-05	0.000676	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—Graves' disease	2.7e-05	0.000666	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—Graves' disease	2.5e-05	0.000615	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—Graves' disease	2.49e-05	0.000615	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.33e-05	0.000574	CbGpPWpGaD
